Important: Formulation and dosage details
Formulation:
Tablets 15mg, 30mg, 45mg
Dosage:
Initially 15mg daily at bedtime increased according to response to 45mg daily as a single dose at bedtime or in 2 divided doses.
We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.
You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits.
To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:
On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.
On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.
Please get in touch with ann.wales3@nhs.scot with any questions.
25/05/24 - Vortioxetine tablets 5mg, 10mg, 20mg SMC1158/16 added.
MHRA advice: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery (January 2021) (www.gov.uk).
MHRA advice: Methylthioninium chloride (methylene blue): update on central nervous system (CNS) toxicity (December 2014) (www.gov.uk).
Tablets 37.5mg, 75mg
Depressive illness: initially 75mg daily in 2 divided doses increased if necessary after several weeks to 150mg daily in 2 divided doses. In severely depressed or hospitalised patients, maximum 375mg daily.
Refer to BNF for other indications.
Modified release capsules 75mg, 150mg
75mg daily increased if necessary after at least 3 to 4 weeks to 150mg once daily; maximum 375mg once daily.
Refer to BNF for other indications.
The immediate-release twice-daily tablets are the more cost-effective option and should be considered first choice unless once-daily dosing is an advantage for individual patients.
Tablets 5mg, 10mg, 20mg (Restricted: Specialist recommendation only)
SMC1158/16: the treatment of major depressive episodes in adults.
SMC restriction: patients who have experienced an inadequate response (either due to lack of
adequate efficacy and/or safety concerns/intolerability) to two or more previous antidepressants.